At a time when there is a worldwide health alert due to the increase in cases of smallpox known as monkeypox or Mpox, research centers and the pharmaceutical industry are in a race against the clock to ‘ find a vaccine that fights more. effectively.
Colombia is participating in that effort. According to the press agency of the National University (Unimedos), the clinical study of the “LC16” vaccine, led by researchers from this faculty, has already completed the vaccination stage and is currently being ‘ monitor the participants to obtain results on their effectiveness, which would be expected by the end of 2024.
The clinical trial began earlier this year and focuses on the LC16 vaccine, developed by the Japanese company KM Biologics, one of three recommended by the World Health Organization (WHO) to prevent Mpox disease, which is transmitted mainly through direct contact with blood, body. fluids and skin wounds, or indirect contact with contaminated surfaces. The aim of the research was to gain knowledge about the behavior of vaccines and their effectiveness.
According to infectious disease doctor Carlos Álvarez, professor at the UNAL Faculty of Medicine and coordinator of national studies on covid-19, “the study was approved by Invima in December 2023, and the vaccination phase began in February 2023. 2024 in Bogotá. “
Although the vaccines that Colombia received (as a donation from the Japanese government) were originally developed to treat human smallpox, they were modified to reduce the violence of this infectious disease which, according to the report of the Ministry of Health , left 4,257 cases reported. in the country since the revolution began in 2022.
2024-08-26 01:12:48
#national #studies #vaccination #Mpox
